Objectives Observational studies suggest that acid suppression may worsen outcomes among patients infected with SARS-CoV-2. The objectives of this embedded substudy of a randomised controlled trial ...
The ASCEND-ATTR study builds on the Phase 3 ATTRibute-CM CMR substudy results previously shared here, which indicated treatment with acoramidis ...
A recent clinical trial reveals how a daily statin pill may prevent heart attacks and strokes in people with HIV. In this substudy of the phase 3 Randomized Trial to Prevent Vascular Events in HIV ...
COURAGE Substudy: Anatomy Trumps Ischemia for Predicting Outcomes Among patients with stable ischemic heart disease, baseline assessment of anatomic burden predicts future events, but evaluation of ...
A long-standing request to clarify data irregularities in a 2021 ISCHEMIA substudy resulted in the publication of one correction, with a second correction in the works. Further, the lone cardiac ...
Adding PCI to optimal medical therapy didn't improve clinical end points among the patients with stable CAD randomized in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug ...
LOS ANGELES, CA—Among medically managed patients with acute coronary syndromes (ACS) but no ST-segment elevation, prasugrel is associated with lower platelet reactivity than clopidogrel, irrespective ...
Neoadjuvant toripalimab plus chemotherapy for resectable stage II-IIIB non-squamous non-small cell lung cancer with EGFR mutations: A multi-center, multi-cohort, exploratory study. This is an ASCO ...
Phase 1/2 dose escalation/expansion study of REGN10597 (anti–PD-1–IL2Rα-IL2) in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary Cancers Symposium ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Hosted on MSN
Daiichi Sankyo’s ADC push in gastroesophageal cancer: What substudy 06D means for investors
Daiichi Sankyo Company (DSKYF) announced an update on their ongoing clinical study. Study Overview: Substudy 06D, formally titled “A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results